Companies › Laboratorios Silanes S.A. de C.V.
2 active drug programs in 32 registered trials: 21 Phase 2, 5 Phase 4, 3 Phase 3, 3 Phase 1; Neurology, Immunology, Other, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Etoricoxib Cyclooxygenase-2 inhibitor | PTGS2 | Phase 3 | Gout Arthritis; Parkinson Disease; Orthodontic Pain (D013850) | Dec 2026 |
| Celecoxib Cyclooxygenase-2 inhibitor | PTGS2 | Phase 3 | Joint Pain; Shoulder Arthropathy; Pain, Postoperative; Surgery … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03825809 | Celecoxib | Phase 2 | Narcotic Use | Other | Jan 2020 |
| NCT05488847 | Celecoxib | Phase 4 | Shoulder Arthropathy | Other | Dec 2024 |
| NCT07559682 | Etoricoxib | Phase 1 | Orthodontic Pain (D013850) | Other | Aug 2025 |
| NCT07559682 | Celecoxib | Phase 1 | Orthodontic Pain (D013850) | Other | Aug 2025 |
| NCT06863636 | Celecoxib | Phase 3 | Joint Pain | Immunology | Oct 2025 |
| NCT06863636 | Celecoxib | Phase 3 | Joint Pain | Immunology | Oct 2025 |
| NCT02574728 | Celecoxib | Phase 2 | Cancer | Oncology | Jun 2026 |
| NCT07174570 | Celecoxib | Phase 2 | Advanced Hepatocellular Carcinoma | Oncology | Nov 2026 |
| NCT07246278 | Celecoxib | Phase 1 | Parkinson Disease | Neurology | Nov 2026 |
| NCT05637086 | Celecoxib | Phase 2 | Epilepsy | Neurology | Dec 2026 |
| NCT05731726 | Celecoxib | Phase 2 | pMMR | Oncology | Dec 2026 |
| NCT06863701 | Etoricoxib | Phase 3 | Gout Arthritis | Immunology | Dec 2026 |
| NCT06379425 | Celecoxib | Phase 4 | Pain, Postoperative | Neurology | Jan 2027 |
| NCT01344200 | Celecoxib | Phase 2 | Pharmacokinetics of Celecoxib in Children | Other | Feb 2027 |
| NCT05722002 | Celecoxib | Phase 4 | Surgery | Other | Feb 2027 |
| NCT07049185 | Celecoxib | Phase 2 | Esophageal Squamous Cell Carcinoma | Oncology | Mar 2027 |
| NCT03926338 | Celecoxib | Phase 2 | Colorectal Cancer | Oncology | Apr 2027 |
| NCT05434065 | Celecoxib | Phase 2 | Intracerebral Hemorrhage | Neurology | Jul 2027 |
| NCT07150949 | Celecoxib | Phase 2 | Locally Advanced Rectal Cancer | Oncology | Aug 2027 |
| NCT06505187 | Celecoxib | Phase 2 | Parotidectomy | Other | Sep 2027 |
| NCT07370532 | Etoricoxib | Phase 2 | Parkinson Disease | Neurology | Nov 2027 |
| NCT07809893 | Celecoxib | Phase 2 | Colorectal Cancer | Oncology | Dec 2027 |
| NCT07494565 | Celecoxib | Phase 2 | Diffuse Large B-Cell Lymphoma (DLBCL) | Oncology | Mar 2028 |
| NCT06245109 | Celecoxib | Phase 4 | Knee Osteoarthritis | Immunology | Mar 2028 |
| NCT06903858 | Celecoxib | Phase 2 | Colorectal Cancer | Oncology | Apr 2028 |
| NCT07076069 | Celecoxib | Phase 4 | Rotator Cuff Repairs | Other | Jun 2028 |
| NCT07597902 | Celecoxib | Phase 2 | Post-acute Sequelae of COVID-19 | Infectious disease | Jun 2028 |
| NCT07154316 | Celecoxib | Phase 2 | Colorectal Cancer | Oncology | Aug 2028 |
| NCT03498326 | Celecoxib | Phase 2 | Pancreatic Cancer | Oncology | Mar 2030 |
| NCT01356290 | Celecoxib | Phase 2 | Medulloblastoma Recurrent | Oncology | Apr 2030 |
| NCT00268476 | Celecoxib | Phase 2 | Prostate Cancer | Oncology | Dec 2030 |
| NCT03026140 | Celecoxib | Phase 2 | Colon Carcinoma | Oncology | Mar 2032 |
ZetrOZ Sirnaomics Caribou Biosciences Sana Biotechnology Brainfarma Industria Química e Farmacêutica S/A AFT Pharmaceuticals
AFT Pharmaceuticals Cartesian Therapeutics Brainfarma Industria Química e Farmacêutica S/A Epygenix Zhejiang Wenda Pharma Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.